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Incidence of Measles in the United States, 2001–2015
Nakia S. Clemmons, MPH, Gregory S. Wallace, MD, MPH, Manisha Patel, MD, MS, and Paul 
A. Gastañaduy, MD, MPH
Division of Viral Diseases, US Centers for Disease Control and Prevention, Atlanta, Georgia
Through nationwide use of vaccination, endemic measles (ie, a transmission chain lasting 12 
months or longer) was eliminated in the United States in 2000.1 Yet, importations of measles 
from endemic countries continue to occur, leading to outbreaks.2 We describe the incidence 
of measles among US residents and examine temporal trends after elimination.
Methods
Measles is nationally notifiable and clinician reporting to health departments is mandatory in 
every state. Cases are investigated and classified according to standard case definitions3 by 
state health departments and reported to the US Centers for Disease Control and Prevention 
(CDC). Reports of all confirmed cases in the United States from January 2001-December 
2015 were analyzed, including available information on age, vaccination, and importation 
status. Age-specific and yearly incidence rates were calculated by dividing the number of 
cases by corresponding population estimates.4 Changes in incidence over time were 
evaluated using negative binomial regression models. Patients were considered vaccinated if 
they had documented receipt of 1 or more doses of a measles-containing vaccine. 
Internationally imported cases had an exposure period outside the United States (7–21 days 
before rash onset) and rash onset within 21 days of entry into the country. Trends in the 
proportion of cases that were imported and vaccinated were evaluated by Cochran-Armitage 
tests. Analyses of incidence and vaccination status were restricted to US residents so census 
data could be used and to assess US-based vaccine recommendations; analyses of 
importation status were based on all reported cases, including foreign visitors. Analyses 
were conducted using SAS (SAS Institute), version 9.3. Statistical significance was defined 
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as a 2-sided P value of less than .05. The CDC determined the study was exempt from 
review.
Results
From 2001 through 2015, 1789 measles cases were reported among US residents (median 
age, 15 years [range, 0–89]; female, 47.1%). Most were unvaccinated (1243 patients 
[69.5%]) or had unknown vaccination status (316 patients [17.7%]); in those 30 years or 
older, 48.1% had unknown vaccination status (Table 1). Overall, 535 of 2012 measles cases 
(26.6%) were imported; 1477 (73.4%) were acquired in the United States.
Measles incidence was 0.39 (95% CI, 0.37–0.41) per million population. Incidence per 
million population was highest in infants aged 6 to 11 months (5.44 [95% CI, 4.67–6.34]) 
and toddlers aged 12 to 15 months (5.38 [95% CI, 4.45–6.51]). Measles rates declined with 
age beginning at 16 months.
The annual number of measles cases varied between 24 and 658, and incidence per million 
population varied between 0.08 (95% CI, 0.05–0.12) and 2.06 (95% CI, 1.91–2.22) (Table 
2). Higher incidence per million population was noted over time, from 0.28 (95% CI, 0.22–
0.35) in 2001 to 0.56 (95% CI, 0.48–0.65) in 2015 (P < .001). The proportion of cases that 
were imported and vaccinated also varied by year but decreasing trends were observed. 
Imported cases ranged between 9.5% and 73.0% of all cases and decreased from 46.6% 
(95% CI, 37.2%–56.1%) in 2001 to 14.7% (95% CI, 10.0%–20.5%) in 2015 (P < .001). 
Vaccinated patients ranged between 5.5% and 29.6% of US cases and decreased from 29.6% 
(95% CI, 20.0%–40.8%) in 2001 to 20.2% (95% CI, 14.6%–26.9%) in 2015 (P < .001).
Discussion
The annual incidence of measles in the United States remained extremely low (<1 case/
million population), in line with the absence of indigenous transmission5 and compared with 
incidence worldwide (40 cases/million population).6 Relative increases in measles rates 
were observed over the period. Ten of 13 outbreaks with 20 or more cases occurred after 
2010.1,2 The concurrent increase in incidence and declines in the proportion of imported and 
vaccinated cases (signifying relative increases in US-acquired and unvaccinated cases) may 
suggest increased susceptibility and transmission after introductions in certain 
subpopulations. Given modest changes and year-to-year variability, cautious interpretation is 
warranted.
The declining incidence with age, the high proportion of unvaccinated cases, and the decline 
in the proportion of vaccinated cases despite rate increases suggest that failure to vaccinate, 
rather than failure of vaccine performance, may be the main driver of measles transmission, 
emphasizing the importance of maintaining high vaccine coverage.
Limitations include lack of verifiable immunization on 48% of adults and the possibility of 
reporting changes, although sustained surveillance adequacy has been documented.1 
Concerns about susceptibility pockets underscore the need for continued surveillance and 
rapid containment strategies.
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